SARS-CoV-2 Spike Antibody (9F7E4) - Alpha Variant, B.1.1.7, UK - BSA Free Summary
Antibody was raised against a peptide corresponding to 12 amino acids near the center of SARS-CoV-2 Alpha variant (B.1.1.7) Spike protein. The immunogen is located within 650-700 amino acids of SARS-CoV-2 Alpha Variant (B.1.1.7, UK) Spike protein.
May cross-react with several virus of interest (VOI) variant lineages that contains P681H mutation, including B.11.318, B.1.621, B.1.621.1, P.3. But all of these lineages are rarely present in current pandemic.
Peptide affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
- Western Blot 1 ug/ml
Antibody can specifically detect SARS-CoV-2 Alpha Variant (B.1.1.7, UK) S1 protein, but not SARS-CoV-2 WT Spike S1 protein by ELISA and WB. It can also detect mutant peptide, but not WT peptide.
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.02% Sodium Azide
Peptide affinity purified
Alternate Names for SARS-CoV-2 Spike Antibody (9F7E4) - Alpha Variant, B.1.1.7, UK - BSA Free
- 2019-nCoV S Protein
- 2019-nCoV Spike
- COVID-19 Spike
- Human coronavirus spike glycoprotein
- Peplomer protein
- S glycoprotein
- S Protein
- SARS-COV-2 S protein
- SARS-COV-2 Spike glycoprotein
- SARSCOV2 Spike protein
- Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
- Spike glycoprotein
- surface glycoprotein
The SARS-CoV-2 Spike protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The spike protein is the largest of the structural proteins, which also include the membrane (M), envelope (E), and nucleocapsid (N) proteins (1,2). The SARS-CoV-2 spike protein is a 1273 amino acid (aa) heterotrimeric class I fusion protein with each monomer having a theoretical molecular weight of approximately 180 kDa (1). The club-shaped spike protein contains several functional regions and domains including the S1 globular head region which contains the N-terminal receptor-binding domain (RBD) and the S2 stem region that contains the C-terminal fusion domain, two heptad regions, a transmembrane domain, and a cytoplasmic tail (1,2). The viral spike protein is critical for attachment of the virus with the host cell, resulting in fusion and virus entry into the cell (1,2). More specifically, the RBD of the spike protein is responsible for binding to the cell surface receptor angiotensin converting enzyme 2 (ACE2) (1,2). This spike-ACE2 interaction results in a conformational change permitting furin cleavage between the S1 and S2 domains and then cleavage at S2' by TMPRRS2, or another protease, allowing membrane fusion (1,2).
Given the critical role of the spike protein RBD in the interaction with the ACE2 receptor and viral entry, a number of neutralizing antibodies against the RBD have been developed as potential therapeutics for treating COVID-19 (3). These antibodies bind the RBD domain on the S1 subunit inhibiting the interaction with ACE2 (3). However, more studies need to be done as neutralizing antibodies can result in antibody-dependent enhancement, in which the viral entry and replication within the host cell is increased (4). One potential way to combat antibody-dependent enhancement is the use of nanobodies (4). Furthermore, there are currently several vaccine strategies that are in clinical trials, or recently federally approved, that utilize the spike protein in different forms (e.g. full length, S1 RBD, RBD-Fc, N-terminal) for protecting against SARS-CoV-2 infection (4,5). These vaccine strategies include DNA vaccines, viral vector-based vaccines, RNA vaccines, and subunit vaccines (4,5).
1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658
2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.
3. Ho M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antibody Therapeutics. https://doi.org/10.1093/abt/tbaa009
4. Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020). Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research. https://doi.org/10.1016/j.virusres.2020.198141
5. Sternberg, A., & Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences. https://doi.org/10.1016/j.lfs.2020.118056
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed
for 1 year from date of receipt.
Publications for SARS-CoV-2 Spike Antibody (NBP3-11941) (0)
There are no publications for SARS-CoV-2 Spike Antibody (NBP3-11941).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for SARS-CoV-2 Spike Antibody (NBP3-11941) (0)
There are no reviews for SARS-CoV-2 Spike Antibody (NBP3-11941).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for SARS-CoV-2 Spike Antibody (NBP3-11941) (0)
Additional SARS-CoV-2 Spike Products
Bioinformatics Tool for SARS-CoV-2 Spike Antibody (NBP3-11941)
Discover related pathways, diseases and genes to SARS-CoV-2 Spike Antibody (NBP3-11941). Need help?
Read the Bioinformatics Tool Guide
for instructions on using this tool.
Blogs on SARS-CoV-2 Spike